Additionally, by targeting inflammatory cascades such as the calpain/calpastatin system and the IL-1α/IL-1β to IL-1Ra ratio, we can then potentially halt the inflammatory-mediated corneal thinning seen in KC. The gene discussed is IL1B; the disease is keratoconus.